GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemiaEric Padron, Pearlie K. Epling‐Burnette, Eun Hee Kim et al.|Blood|2013Cited by 155
GM-CSF Signaling Abnormalities in Chronic Myelomonocytic LeukemiaEric Padron, Pearlie K. Epling‐Burnette, Jeffrey S. Painter et al.|Blood|2011Cited by 3
Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML)Eric Padron, Pearlie K. Epling‐Burnette, Alan F. List et al.|Blood|2012Cited by 1